Astro Pak launches decontamination services subsidiary

Published: 26-Jan-2010
Hi Tech Manufacturing Finance Cleaning

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.

The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.

The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.

Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.

In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
  • Companies:
  • Instant Cleanroom Solutions
See more

You may also like

Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Read more
Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena

Trending Articles

  1. Biologics at a turning point: complexity, AI and the road to 2026 Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
  2. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Building a beta-lactam powerhouse: Gaelic’s strategic leap with Athlone In December 2025, Gaelic Laboratories, a world-class manufacturer of beta-lactam (penicillin) products, acquired Athlone Laboratories, another leading developer and supplier of oral dose beta-lactams
  4. Ofichem Group to acquire drug formulation development specialist, Avivia Ofichem will now be able to offer its clients a range of early-stage development services, from analytical method development to excipient characterisation
  5. £12 million in grants to tackle superbugs in a global context The researchers will use a range of approaches, from clinical and microbiological to geography, modelling and social sciences, to identify, prioritise and understand the specific problem of AMR across different communities and environments in Kenya, Tanzania, Uganda, Malawi and Thailand

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies

Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Finance

EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups

The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance

Fresh capital flows into neurodegeneration, cancer and vascular-access developers

A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access
Finance

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget
Subscribe now